(NASDAQ: HUMA) Humacyte's forecast annual revenue growth rate of 276.48% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.27%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.52%.
Humacyte's revenue in 2026 is $2,016,000.On average, 7 Wall Street analysts forecast HUMA's revenue for 2026 to be $1,438,017,763, with the lowest HUMA revenue forecast at $957,346,394, and the highest HUMA revenue forecast at $1,953,324,112. On average, 7 Wall Street analysts forecast HUMA's revenue for 2027 to be $5,955,662,572, with the lowest HUMA revenue forecast at $2,393,365,984, and the highest HUMA revenue forecast at $12,447,057,252.
In 2028, HUMA is forecast to generate $27,013,064,870 in revenue, with the lowest revenue forecast at $11,140,030,763 and the highest revenue forecast at $44,013,067,970.